Literature DB >> 30363434

Role of Corpus Callosum Volumetry in Differentiating the Subtypes of Progressive Supranuclear Palsy and Early Parkinson's Disease.

Abhishek Lenka1,2, Shaik Afsar Pasha2, Sandhya Mangalore3, Lija George2, Ketan Ramakant Jhunjhunwala1,2, Bhawani Shankar Bagepally1, Rajini M Naduthota2, Jitender Saini3, Ravi Yadav2, Pramod Kumar Pal2.   

Abstract

BACKGROUND AND
OBJECTIVE: Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disorder. Classic PSP or Richardson-Steele phenotype (PSP-RS) and parkinsonian phenotype (PSP-P) are the common subtypes of PSP. At the early stage, differentiating the subtypes of PSP as well as differentiating PSP from other parkinsonian disorders, especially Parkinson's disease (PD) is challenging. Microstructural abnormalities of corpus callosum (CC) have been reported both in PSP and PD. The objective of this study was to compare the volumes of various segments of CC between patients with PSP-P, PSP-RS, and early PD.
METHODOLOGY: This study included 32 patients with PSP (RS: 18, P: 14), 20 patients with early PD, and 25 controls. All subjects underwent 3-Tesla MRI. An automated surface-based analysis package (FreeSurfer) was used to divide CC into five segments: anterior (CC1), midanterior (CC2), central (CC3), midposterior (CC4), and posterior (CC5). Volumes of these segments were compared among the four groups.
RESULTS: The PSP-RS group had significantly lower CC volume in all segments except in CC1 and CC5, whereas the volumes of the five segments of CC were comparable among PSP-P, PD and controls. The PSP-RS group had lower CC3 volume compared to the PSP-P group, and the PSP-RS group had lower volume of both CC2 and CC3 compared to the PD group.
CONCLUSIONS: The lower volume of the central segment of CC (CC3) might help in differentiating PSP-RS from PSP-P. There is no significant difference in the pattern of CC atrophy in PSP-P and early PD. Studies with higher sample sizes are warranted to confirm the results of our study.

Entities:  

Keywords:  FreeSurfer; MRI; PD; PSP; Parkinson's disease; corpus callosum; progressive supranuclear palsy

Year:  2017        PMID: 30363434      PMCID: PMC6174399          DOI: 10.1002/mdc3.12473

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  31 in total

Review 1.  The role of the corpus callosum in interhemispheric transfer of information: excitation or inhibition?

Authors:  Juliana S Bloom; George W Hynd
Journal:  Neuropsychol Rev       Date:  2005-06       Impact factor: 7.444

2.  Topography of the human corpus callosum revisited--comprehensive fiber tractography using diffusion tensor magnetic resonance imaging.

Authors:  Sabine Hofer; Jens Frahm
Journal:  Neuroimage       Date:  2006-07-18       Impact factor: 6.556

3.  Anatomy of the corpus callosum reveals its function.

Authors:  Eric Mooshagian
Journal:  J Neurosci       Date:  2008-02-13       Impact factor: 6.167

4.  Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy.

Authors:  A Padovani; B Borroni; S M Brambati; C Agosti; M Broli; R Alonso; P Scifo; G Bellelli; A Alberici; R Gasparotti; D Perani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

5.  Abnormal cortical synaptic plasticity in primary motor area in progressive supranuclear palsy.

Authors:  Antonella Conte; Daniele Belvisi; Matteo Bologna; Donatella Ottaviani; Giovanni Fabbrini; Carlo Colosimo; David R Williams; Alfredo Berardelli
Journal:  Cereb Cortex       Date:  2011-06-15       Impact factor: 5.357

6.  The Mini-Mental State Examination.

Authors:  M F Folstein; L N Robins; J E Helzer
Journal:  Arch Gen Psychiatry       Date:  1983-07

7.  A clinical rating scale for progressive supranuclear palsy.

Authors:  Lawrence I Golbe; Pamela A Ohman-Strickland
Journal:  Brain       Date:  2007-04-02       Impact factor: 13.501

8.  White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study.

Authors:  G Gattellaro; L Minati; M Grisoli; C Mariani; F Carella; M Osio; E Ciceri; A Albanese; M G Bruzzone
Journal:  AJNR Am J Neuroradiol       Date:  2009-04-02       Impact factor: 3.825

9.  Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: a quantitative analysis of six cases.

Authors:  P R Hof; A Delacourte; C Bouras
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

10.  Diffusion tensor imaging of Parkinson's disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study.

Authors:  Amanda Worker; Camilla Blain; Jozef Jarosz; K Ray Chaudhuri; Gareth J Barker; Steve C R Williams; Richard G Brown; P Nigel Leigh; Flavio Dell'Acqua; Andrew Simmons
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

View more
  4 in total

Review 1.  "Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.

Authors:  Ján Necpál; Miroslav Borsek; Bibiána Jeleňová
Journal:  Neurol Sci       Date:  2021-09-17       Impact factor: 3.307

2.  Longitudinal Macro/Microstructural Alterations of Different Callosal Subsections in Parkinson's Disease Using Connectivity-Based Parcellation.

Authors:  Jingjing Wu; Tao Guo; Cheng Zhou; Xiaojun Guan; Ting Gao; Min Xuan; Quanquan Gu; Peiyu Huang; Zhe Song; Jiali Pu; Yaping Yan; Jun Tian; Baorong Zhang; Xiaojun Xu; Minming Zhang
Journal:  Front Aging Neurosci       Date:  2020-11-04       Impact factor: 5.750

3.  A New Statistical Framework for Corpus Callosum Sub-Region Characterization Based on LBP Texture in Patients With Parkinsonian Disorders: A Pilot Study.

Authors:  Debanjali Bhattacharya; Neelam Sinha; Shweta Prasad; Pramod Kumar Pal; Jitender Saini; Sandhya Mangalore
Journal:  Front Neurosci       Date:  2020-05-28       Impact factor: 4.677

4.  Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease.

Authors:  Conor Owens-Walton; Chris Adamson; Mark Walterfang; Sara Hall; Danielle van Westen; Oskar Hansson; Marnie Shaw; Jeffrey C L Looi
Journal:  Eur J Neurosci       Date:  2022-03-22       Impact factor: 3.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.